Table 1:
Demographics | Derivation cohort (N=398) |
Validation Cohort (N=94) |
P value |
---|---|---|---|
Age (Mean(SD)) | 59±8 | 56±7 | 0.0009 |
Male sex N (%) | 335(84.1%) | 54(55%) | <0.0001 |
Education (Median (IQR)) | 13 (12, 14) | 13 (12, 15) | 0.56 |
CHE on PHES N (%) | 201(50.5%) | 43(44%) | 0.23 |
MELD score (Mean(SD)) | 12.5 (5.7) | 12.4 (6.0) | 0.88 |
Rifaximin N (%) | 152(38%) | 28(30%) | 0.13 |
Prior Overt HE N (%) | 164(41%) | 32(32.2%) | 0.11 |
EncephalApp (Mean (SD)) seconds | |||
Total Off Time | 85.5(74.5,101) | 78(65,93) | 0.0002 |
Total On Time | 103(89,125) | 94(78,108) | 0.0003 |
Total OffTime+OnTime | 189(163,225) | 172 (147,201) | 0.0002 |
CHE: covert hepatic encephalopathy, PHES: psychometric hepatic encephalopathy score, HE: hepatic encephalopathy; all patients with prior HE were on lactulose.